ATE374214T1 - Monoklonaler anti-cd-40-antikörper - Google Patents

Monoklonaler anti-cd-40-antikörper

Info

Publication number
ATE374214T1
ATE374214T1 AT02720634T AT02720634T ATE374214T1 AT E374214 T1 ATE374214 T1 AT E374214T1 AT 02720634 T AT02720634 T AT 02720634T AT 02720634 T AT02720634 T AT 02720634T AT E374214 T1 ATE374214 T1 AT E374214T1
Authority
AT
Austria
Prior art keywords
antibody
monoclonal anti
agonistically
antagonistically
acting
Prior art date
Application number
AT02720634T
Other languages
English (en)
Inventor
Toshifumi Mikayama
Hitoshi Yoshida
Walker Force
Xingjie Chen
Nobuaki Takahashi
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/013672 external-priority patent/WO2001083755A2/en
Priority claimed from US09/844,684 external-priority patent/US7063845B2/en
Priority claimed from US10/040,244 external-priority patent/US20030059427A1/en
Application filed by Kirin Brewery filed Critical Kirin Brewery
Application granted granted Critical
Publication of ATE374214T1 publication Critical patent/ATE374214T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02720634T 2001-04-27 2002-04-26 Monoklonaler anti-cd-40-antikörper ATE374214T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2001/013672 WO2001083755A2 (en) 2000-04-28 2001-04-27 Human anti-cd40 antibodies and methods of making and using same
US09/844,684 US7063845B2 (en) 2000-04-28 2001-04-27 Human anti-CD40 antibodies
JP2001142482 2001-05-11
JP2001310535 2001-10-05
US10/040,244 US20030059427A1 (en) 2000-04-28 2001-10-26 Isolation and characterization of highly active anti-CD40 antibody

Publications (1)

Publication Number Publication Date
ATE374214T1 true ATE374214T1 (de) 2007-10-15

Family

ID=32601004

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02720634T ATE374214T1 (de) 2001-04-27 2002-04-26 Monoklonaler anti-cd-40-antikörper

Country Status (8)

Country Link
US (4) US7193064B2 (de)
EP (2) EP2009027B1 (de)
CN (1) CN101508734A (de)
AT (1) ATE374214T1 (de)
AU (1) AU2009200017A1 (de)
CA (1) CA2658221C (de)
DK (1) DK1391464T3 (de)
PT (1) PT1391464E (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
ATE374214T1 (de) * 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
TWI353992B (en) * 2003-07-22 2011-12-11 Schering Ag Rg1 antibodies and uses thereof
AU2004266242A1 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2005063981A1 (ja) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗cd40抗体の変異体
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
DK1889065T3 (da) 2005-05-18 2013-09-02 Xoma Technology Ltd Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent
DK2447283T3 (en) * 2005-09-07 2015-08-31 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase 1 (ALK-1)
CN101426817B (zh) 2006-04-21 2013-07-10 诺华有限公司 拮抗性抗-cd40抗体药物组合物
CA2652599C (en) 2006-05-03 2019-09-24 Ross Kedl Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
CN103172743B (zh) * 2006-12-01 2015-04-08 梅达雷克斯有限责任公司 结合cd22的人抗体及其用途
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2010104748A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
MX2011009438A (es) 2009-03-10 2012-04-02 Baylor Res Inst Anticuerpos anti-cd40 y usos de los mismos.
ES2635080T3 (es) * 2009-03-10 2017-10-02 Baylor Research Institute Vacunas contra el cáncer dirigidas a células presentadoras de antígenos
EP2949671A1 (de) 2009-10-12 2015-12-02 Pfizer Inc Krebstherapie
BR112012024713B1 (pt) * 2010-03-31 2021-02-17 Boehringer Ingelheim International Gmbh anticorpo humanizado, seus usos e composição farmacêutica que o compreende
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
ES2617983T3 (es) * 2011-01-10 2017-06-20 Ct Atlantic Ltd. Terapia de combinación que incluye anticuerpos de unión a antígenos asociados a tumores
CA2852056C (en) * 2011-03-11 2021-08-10 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
WO2012145183A2 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EP3508500A1 (de) 2011-04-29 2019-07-10 Apexigen, Inc. Anti-cd40-antikörper und verfahren zur verwendung
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
EP3925977A1 (de) 2012-10-30 2021-12-22 Apexigen, Inc. Anti-cd40-antikörper und verfahren zur verwendung
GB201316644D0 (en) * 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
WO2015106281A1 (en) 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
US20160015803A1 (en) * 2014-07-18 2016-01-21 Ross Kedl Immunostimulatory combinations and use thereof
CN106573981A (zh) 2014-08-12 2017-04-19 鳄鱼生物科学公司 利用抗cd40抗体的组合疗法
PL3212230T3 (pl) 2014-10-29 2021-07-26 Seagen Inc. Dawkowanie i podawanie niefukozylowanych przeciwciał anty-CD40
EP3229586A4 (de) 2014-12-10 2018-10-24 Regents of the University of Minnesota Genetisch modifizierte zellen, gewebe und organe zur behandlung von krankheiten
WO2016109310A1 (en) 2014-12-31 2016-07-07 Checkmate Pharmaceuticals, Llc Combination tumor immunotherapy
KR102661078B1 (ko) * 2015-05-29 2024-05-23 애브비 인코포레이티드 항-ｃｄ40 항체 및 그의 용도
DK3307322T3 (da) 2015-09-04 2021-04-19 Primatope Therapeutics Inc Humaniserede anti-cd40-antistoffer og anvendelser deraf
BR112018006360A2 (pt) * 2015-09-30 2018-10-09 Janssen Biotech Inc anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
WO2017124001A2 (en) * 2016-01-14 2017-07-20 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for foxp3-derived peptides
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
EP3551046B1 (de) 2016-12-07 2023-07-19 Biora Therapeutics, Inc. Verfahren, vorrichtungen und systeme zur detektion des magen-darm-trakts
EP4108183A1 (de) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Behandlung einer erkrankung des gastrointestinaltraktes mit einem immunmodulatorischen mittel, das mit einer einnehmbaren vorrichtung freigesetzt wird
US11866465B2 (en) 2017-04-27 2024-01-09 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
CA3064298A1 (en) * 2017-06-01 2018-12-06 Shanghai Hengrui Pharmaceutical Co., Ltd. Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
CA3075221A1 (en) * 2017-09-19 2019-03-28 Mab Discovery Gmbh Agonistic cd40 antibodies
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
AU2018391831B2 (en) * 2017-12-20 2022-08-04 Harbour Biomed (Shanghai) Co., Ltd Antibodies binding CTLA-4 and uses thereof
EP3749330A4 (de) 2018-02-06 2021-11-17 The General Hospital Corporation Repeat-rna als biomarker der tumorimmunreaktion
WO2019204756A1 (en) * 2018-04-20 2019-10-24 Lyvgen Biopharma Co., Ltd. Anti-cd40 antibodies and uses thereof
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
KR20210070317A (ko) 2018-09-28 2021-06-14 리브젠 바이오파마 코., 엘티디. 조작된 Fc 도메인을 갖는 항-CD40 결합 분자 및 그의 치료적 용도
WO2020070288A1 (en) 2018-10-05 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
EP3883634A1 (de) 2018-11-19 2021-09-29 Progenity, Inc. Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika
EP3892634A4 (de) * 2018-11-30 2022-11-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd40-antikörper, antigenbindendes fragment und pharmazeutische verwendung davon
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
EP4076434A1 (de) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Kombination von antikrebstherapien mit induktoren der eisenabhängigen zellulären zerlegung
KR20220127847A (ko) 2020-01-10 2022-09-20 더 브리검 앤드 우먼즈 하스피털, 인크. 뇌암을 치료하기 위해 혈액-뇌 장벽을 통해 면역요법제를 전달하기 위한 방법 및 조성물
US20230227567A1 (en) * 2020-06-04 2023-07-20 Selvax Pty Ltd Agonist anti-cd40 antibodies
EP4172323A1 (de) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Manipulierte viren zur förderung der a-otransmission und deren verwendung bei der behandlung von krebs
WO2022036495A1 (en) * 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CN112409486B (zh) * 2020-11-26 2022-05-20 杭州百凌生物科技有限公司 一种抗cd40抗体及其应用
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CN115403670A (zh) 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023020475A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Cd40-targetting antibodies and uses thereof
CN117500816A (zh) 2021-08-26 2024-02-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024401A (en) 1975-11-17 1977-05-17 General Electric Company X-ray apparatus
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
EP0434879A1 (de) 1989-12-14 1991-07-03 Schering-Plough Verfahren zur Herstellung von faktorabhÀ¤ngigen menschlichen B-Zellinien
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH08503121A (ja) 1991-12-10 1996-04-09 デイナ・フアーバー・キヤンサー・インステイテユート 中和反応性ヒト抗−ｇｐ１２０組換え抗体、それをコードするｄｎａおよびその使用
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
EP1834671A3 (de) 1992-07-09 2013-05-22 Novartis Vaccines and Diagnostics, Inc. Ein Verfahren zur Erregung von Antikörpern gegen Zelloberflächemoleküle
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
ATE255906T1 (de) * 1993-10-01 2003-12-15 Immunex Corp Antikörper gegen cd40
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
WO1998037757A1 (fr) 1997-02-28 1998-09-03 Kirin Beer Kabushiki Kaisha Cellules multipotentes comprenant des genes intrinseques dissocies
JP2002502823A (ja) 1998-02-04 2002-01-29 ザ・ジェネラル・ホスピタル・コーポレイション 移植における補刺激遮断および混合キメラ現象
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
JP2002512776A (ja) 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション 免疫原性の低下したモノクローナル抗体
WO1999061051A1 (en) 1998-05-26 1999-12-02 Genitrix, Lcc Compositions and methods of modulating an immune response to an antigen
AU4954899A (en) 1998-06-26 2000-01-17 Trustees Of Dartmouth College Methods and compositions for modulating antigen-specific immunological (humoral)responses by targeting such antigen to apcs in conjunction with anti-cd40 ligan d administration
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001016180A2 (en) * 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
AU1072701A (en) 1999-10-04 2001-05-10 Chiron Corporation Cd40 antagonist for treating psoriasis
JP2001142482A (ja) 1999-11-10 2001-05-25 Nippon Hoso Kyokai <Nhk> 音声字幕化装置
EP1253942A4 (de) 2000-02-01 2004-06-16 Tanox Inc Cd40-bindende und apc-aktivierende moleküle
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
JP2001310535A (ja) 2000-04-28 2001-11-06 Canon Inc 記録装置、および記録ヘッドの濃度むら補正方法
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
WO2002028905A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
ATE374214T1 (de) * 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
WO2003029296A1 (en) 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
NZ538498A (en) 2002-07-30 2009-02-28 Childrens Medical Center Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors

Also Published As

Publication number Publication date
US20100234578A1 (en) 2010-09-16
EP2009027B1 (de) 2014-05-21
CA2658221C (en) 2012-11-27
CA2658221A1 (en) 2002-11-07
CN101508734A (zh) 2009-08-19
EP2009027A1 (de) 2008-12-31
US20090123466A1 (en) 2009-05-14
US20070077242A1 (en) 2007-04-05
US7193064B2 (en) 2007-03-20
US7537763B2 (en) 2009-05-26
EP2011802A2 (de) 2009-01-07
PT1391464E (pt) 2007-11-15
EP2011802A3 (de) 2009-04-15
AU2009200017A1 (en) 2009-02-05
DK1391464T3 (da) 2008-01-14
US20040120948A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
ATE374214T1 (de) Monoklonaler anti-cd-40-antikörper
EP1914243A3 (de) Monoglonaler Antikörper gegen CD40
BR0208013B1 (pt) mecanismo de acionamento para um dispositivo de injeÇço.
NO20040671D0 (no) Emballasje for myke, engangs-kontaktlinser.
NO20041165L (no) Avstengningsanordning.
BR0215188B1 (pt) válvula de gaveta.
ITTO20020003A1 (it) Dispositivo di verifica per veicolo.
ITPD20020236A1 (it) Dispositivo di regolazione a manopola, particolarmente
BR0116998B1 (pt) dispositivo osteossintético.
BR0204689B1 (pt) dispositivo de fixação.
ITTO20020085V0 (it) Proiettore per veicoli.
ITTO20010754A0 (it) Dispositivo di regolazione della posizione di un pedale.
ES1049393Y (es) Dispositivo de ambientacion olorosa multiple.
ITTO20020066V0 (it) Proiettore per veicoli.
BR0116875B1 (pt) conjunto de válvulas.
ES1050791Y (es) Dispositivo de control funcional para cafeteras de hosteleria.
ITTO20020067V0 (it) Proiettore per veicoli.
ES1050837Y (es) Un dispositivo de union.
ES1050767Y (es) Dispositivo higienico-sanitario.
ES1050426Y (es) Dispositivo elevador - nivelador.
ES1049664Y (es) Dispositivo autohinchador.
ES1051818Y (es) Fuente.
ITRE20010020V0 (it) Dispositivo collimatore.
ES1050793Y (es) Dispositivo de fijacion de luminarias.
ITBO20020537A1 (it) Dispositivo valvolare.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1391464

Country of ref document: EP

EEIH Change in the person of patent owner